Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

The release of negative regulators of immune activation (immune checkpoints) that limit
antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Breast cancers are complex ecosystems of malignant cells and the tumour
microenvironment. The composition of these tumour ecosystems and interactions within …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …